Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
AHA 2026
Long-Term Outcomes Among US Medicare Beneficiaries with Non-Cardioembolic Ischemic Stroke
In this observational cohort study of Medicare FFS patients admitted for NCIS, the following was observed:
- High risk of subsequent stroke
Especially pronounced among those with a history of prior stroke
High risk of subsequent cardiovascular events
High economic burden with respect to the index admission and subsequent hospitalizations
Across clinical, functional, and economic outcomes, the burden was consistently greater among patients with a history of prior stroke
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
